A flowgraph model for bladder carcinoma

Similar documents
Modelling the recurrence of bladder cancer

Radical Cystectomy Often Too Late? Yes, But...

The value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Urological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Staging and Grading Last Updated Friday, 14 November 2008

Kyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang

european urology 52 (2007)

THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy

Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive

Effectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up

The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor

Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer

Pharmacologyonline 3: (2006)

Patient Risk Profiles: Prognostic Factors of Recurrence and Progression

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study

The Statistical Analysis of Failure Time Data

Generated by Foxit PDF Creator Foxit Software For evaluation only.

Bas W.G. van Rhijn, M.D., Ph.D., F.E.B.U.*

Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer

EUROPEAN UROLOGY 56 (2009)

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

SUPERFICIAL BLADDER CANCER MANAGEMENT

A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases

Mathematical Modeling for the Tumor Growth in the Bladder


Symptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography

CAN INTRAVESICAL BACILLUS CALMETTE-GUÉRIN REDUCE RECURRENCE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER? A META-ANALYSIS OF RANDOMIZED TRIALS

Statistical analysis of longitudinal studies: how to evaluate changes in risk factor and outcome?

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non Muscle-Invasive Bladder Cancer

Original Article APMC-276

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome

Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Continuous/Discrete Non Parametric Bayesian Belief Nets with UNICORN and UNINET

/05/ /0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer

The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)

BLADDER CANCER: PATIENT INFORMATION

Maintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer

Homogeneous Markov Processes For Breast Cancer Analysis

Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer

Collection of Recorded Radiotherapy Seminars

Non-muscle invasive bladder cancer: Are epicrises the Bermuda Triangle of information transfer?

ONCOLOGY LETTERS 11: , 2016

Haematuria and Bladder Cancer

A Model for the CD4 Cell Counts in an HIV/AIDS Patient and its Application in Treatment Interventions

Bladder cancer - suspected

Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes

Abstract. Objective. Materials and Methods. Results

Intravesical Therapy for Bladder Cancer

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Review Article. Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer

Efficacy and Safety of Hexaminolevulinate Fluorescence Cystoscopy in the Diagnosis of Bladder Cancer

Citation International journal of urology (2. Right which has been published in final f

BLADDER TUMOURS A REVIEW OF 150 PATIENTS TREATED AT THE INSTITUTE OF UROLOGY AND NEPHROLOGY GENERAL HOSPITAL KUALA LUMPUR

Update on bladder cancer diagnosis and management

Landmarking, immortal time bias and. Dynamic prediction

Issues in the Management of High Risk Superficial Bladder Cancer

Next-generation sequencing in non-muscle-invasive bladder cancer a step towards personalized medicine for a superficial bladder tumor

Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer

Non Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC

Beware the BCG Failures: A Review of One Institution's Results

European Urology 46 (2004) 65 72


Role of Re-Resection in Non Muscle-Invasive Bladder Cancer

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida

Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours

Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel

Some interpretational issues connected with observational studies

RESEARCH ARTICLE. Abstract. Introduction. Patients and Methods

imedpub Journals

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.

Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience

INTRAVESICAL THERAPY AND FOLLOW-UP OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER

Non-Muscle-Invasive Bladder Cancer Last Updated Friday, 14 November 2008

Theralase Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated

Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study

HHS Public Access Author manuscript Clin Genitourin Cancer. Author manuscript; available in PMC 2017 August 01.

Bladder Cancer Guidelines

Supplementary Material

Comparisons of Dynamic Treatment Regimes using Observational Data

Novel Methods in the Visualization of Transitional Phenomena

Costing report: Bladder cancer

Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract

Natural History, Recurrence, and Progression in Superficial Bladder Cancer

Objectives. Results. Patients and Methods. Conclusions. associated percentages were used to analyse treatment variables.

Does the Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Improve Survival in Bladder Cancer?

Multiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy

The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study

ENDOSCOPIC URETERECTOMY DURING NEPHROURETERECTOMY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA

Transcription:

A flowgraph model for bladder carcinoma Gregorio Rubio 1, Belén García-Mora 1, Cristina Santamaría 1, and José Luis Pontones 2 1 Instituto de Matemática Multidisciplinar. Universidad Politécnica de Valencia 2 Departamento de Urología. Hospital Universitario La Fe de Valencia Abstract. Superficial bladder cancer has been the subject of numerous studies for many years, but the evolution of the disease still remains not well understood. After the tumor has been surgically removed, it may reappear at a similar level of malignancy or progress to a higher level. The process may be reasonably modeled by means of a Markov process. However, in order to fully model the evolution of the disease, this approach is insufficient. The semi-markov framework allows a more realistic approach, but calculations become frequently intractable. In this context, flowgraph models provide an efficient approach to successfully manage the evolution of superficial bladder carcinoma. Keywords: flowgraph model, bladder carcinoma, Erlang distribution 1 Introduction Bladder tumor is a challenge for urology. It supposes an important public health problem because it is biologically very aggressive and presents a high prevalence in the western countries. Approximately 75 85 % of patients with newly diagnosed bladder carcinoma present non muscle-invasive bladder carcinoma (NMI- BC), which can be managed with transurethral resection (TUR), that is a surgical endoscopic technique used to remove the macroscopic tumor from the inner of the bladder. The object of this study is the NMI-BC, that supposes about 70 % of the total expenses of this disease. Biotechnological advances have allowed us to use different therapeutic procedures (surgery, radiotherapy, chemotherapy, immunotherapy) successfully but still many patients suffer an unfavourable outcome without control of disease. In practice urologists have an important problem: some patients with similar characteristics undergo a different evolution. Consequently, that situation creates a problem with the treatment to be applied. Urologists need tools to accurately predict the real evolution of the disease, that help them to improve treatment modalities and follow-up schemes of non-muscle invasive bladder cancer patients. In this regard an important contribution [1] appeared in European Urology, the official journal of the European Association of Urology. By means of look up tables the probability of recurrence and progression for a patient is provided. corresponding author. IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 547

2 A flowgraph model for bladder carcinoma However only time to first recurrence is considered, and the analysis is reduced to the Cox proportional hazards regression model. Later works have studied the model validation, finding some limitations [2]. Our team has been working with urologists from University Hospital La Fe for the last ten years. We have developed several models trying to capture different aspects of the disease evolution. Our aim for the near future is to detect the most relevant predictive factors, and also to perform an accurate model of the disease evolution. The first objective includes to investigate at the genetic and molecular level, and the second one could be achieved with a suitable multistate model. While the process may be reasonably modeled by means of a Markov process, in order to fully model the evolution of the disease this approach is insufficient. Specifically, it is possible that time spent in a state influences the future evolution of the process, i.e., it not only depends on the current state. The semi-markov framework allows a more realistic approach, but calculations become frequently intractable. In this context, flowgraph models provide an efficient approach for the analysis of time-to-event data, since their introduction in this field a few years ago [3]. The present work is a first step in order to explore the evolution of the recurrence progression process by means of this methodology. The paper is organized as follows: in section 2 we review a few basic concepts of survival analysis and we present the essentials of flowgraph models. Section 3 deals with a simple flowgraph model for the recurrence-progression process in NMI-BC, constructed using a database from La Fe University Hospital of Valencia (Spain). Finally, in section 4 some discussion is given. 2 Survival analysis and flowgraph models 2.1 Survival analysis Survival analysis techniques deal with the analysis of data in the form of times from well-defined time-origin until the occurrence of some particular event or end-point. To summarize survival data there are two key functions: the Survival Function and the Hazard Function. Let T be the random variable associated with the survival time (time until the ocurrence of the event). The Survival Function is S(t) = P(T t) = 1 F (t) where F (t) is the distribution function of T. It expresses the probability that an individual survives from the time origin to some time beyond t. The Hazard Function is given by λ(t) = lim t 0 P( t T < t + t T t), t what expresses the hazard rate or the instantaneous event rate. IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 548

A flowgraph model for bladder carcinoma 3 In survival analysis data are frequently censored [4], what means that the event of interest has not been observed. The time of follow up of those patients must be taken into account, because it informs us of the fact that the individual was free of event until the present moment. For instance we started with 620 patients, of whom 247 underwent a recurrence, 16 a progression, and 358 had censored times, what means that at the time of their last revision they had no recurrence or progression. 2.2 Flowgraph models A flowgraph model is a graphical representation of a multistate model, that consists of directed line segments (branches) connecting the states, namely, a directed graph. The branches are labeled with transmittances, that are the transition probability p ij from state i to state j multiplied by an integral transform G ij (s) of the transition time probability density function (PDF). This transform can be a characteristic function (CF), a moment generating function (MGF), a Laplace transform (LT), or even an empirical transform [5] [6]. Flowgraphs are used to represent semi-markov processes, given that allowed waiting time distributions go beyond the exponential distribution directly linked to Markov processes. For instance, Figure 1 shows the flowgraph of the three-state illness-death model, that we will use in this paper. 1 P 01 M 01 (s) P 12 M 12 (s) P 02 M 02 (s) 0 2 Fig. 1. Three-state illness-death model. The transmittances are combined according to a systematic procedure (see [7], section 2.5), in order to compute the transforms for the transitions of interest. The final step is to invert these transforms to obtain PDFs. Flowgraph models for stochastic networks were introduced by Butler and Huzurbazar [3]. An account of the theory developed up to 2005 may be found in [7]. A recent contribution proposing a prognostic model is [8]. IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 549

4 A flowgraph model for bladder carcinoma 3 A flowgraph model for bladder carcinoma 3.1 Data The database was obtained from La Fe University Hospital of Valencia (Spain). It records clinico-pathological information from 620 patients, followed between January 1995 and January 2010. The mean follow up time for the entire cohort was 3 years and 11 months. The data record several recurrence times. This means that some patients have no recurrence at all, some have one or more recurrences, and some have progression (directly of after some recurrence). In our model we have considered progressions and one recurrence. As stated above, 246 patients underwent a recurrence, 16 a progression, and 358 had censored times. Then, 44 patients were lost. From the remaining 202 patients, 111 underwent again a recurrence, 8 a progression and 83 were censored. 3.2 Flowgraph model Our aim in this paper is to test the flowgraph methodology in this particular problem, and so we perform the simple model of Figure 1. In state 0 the patient is free of disease, after the RTU of the primary tumor. State 1 is the first recurrence, and state 2 is progression. is given in years. The first step is to select a suitable distribution for the waiting time in each transition. Our approach will be to compute the empirical distributions and approximate them using mixtures of Erlang distributions. Specifically we use a linear combination of three Erlang proposed in [9]. The coefficients were calculated by means of a non-negative least squares fit (Lawson-Hanson algorithm [10]). Our aim is to model the overall risk of progression. Therefore we have to calculate the PDF of the overall time to progression. For this we compute the Laplace transform of the global transition from state 0 to state 2. To recover the PDF we use a variant of the inversion algorithm EULER [8]. From this function we obtain the survival function (with regard to progression), that is shown in Figure 5, jointly with the empirical survival function. 4 Discussion Flowgraph methodology is very flexible. It allows the model to incorporate multiple recurrences, and recently also covariates [5]. We may explore many parametric models looking for the distributions that match the data better. Moreover non-parametric approaches are also avalaible [6]. This versatility, along with the inclusion of molecular biomarkers, allow us to expect to get a very accurate model in a not too distant future. Acknowledgments. This study has been funded by Vicerrectorado de Investigación de la Universitat Politécnica de Valéncia. Reference 2406. IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 550

A flowgraph model for bladder carcinoma 5 CDF 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0 2 4 6 8 10 12 Fig. 2. Erlang mixture (smooth line) and empirical distribution (step function) for transition 01. CDF 0.00 0.01 0.02 0.03 0.04 0.05 0 2 4 6 8 10 12 Fig. 3. Erlang mixture (smooth line) and empirical distribution (step function) for transition 02. IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 551

6 A flowgraph model for bladder carcinoma CDF 0.02 0.04 0.06 0.08 0.10 0.12 0 2 4 6 8 10 Fig. 4. Erlang mixture (smooth line) and empirical distribution (step function) for transition 12. Survival 0.95 0.96 0.97 0.98 0.99 1.00 0 2 4 6 8 10 12 Fig. 5. Survival function model (smooth line) and empirical survival function (step function). IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 552

A flowgraph model for bladder carcinoma 7 References 1. Sylvester, R. J., van der Meijden, A. P., Oosterlinck, W., Witjes, J. A., Bouffioux C., Denis, L., Newling, D. W., Kurth, K.: Predicting recurrence and progression in individual patients with stage ta t1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 475 7 (2006) 2. Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martínez-Pieiro, L., Gonzalez, M., Portillo, J., Ojea, A., Pertusa, C., Rodriguez-Molina, J., Camacho, J., Rabadan, M., Astobieta, A., Montesinos, M., Isorna, S., Muntaola, P., Gimeno, A., Blas, M., Martinez-Pieiro, J. A. : The EORTC tables overestimate the risk of recurrence and progression in patients with non muscle-invasive bladder cancer treated with bacillus calmette-guerin: External validation of the EORTC risk tables. Eur. Urol. 60, 423 430 (2011) 3. Butler, R.W, Huzurbazar, A.V.: Stochastic network models for survival analysis. J. Am. Statist. Assoc.. 92, 246 257 (1997) 4. Klein, J.P., Moeschberger, M.L.: Survival Analysis. Techniques for Censored and Truncated Data, Second Edition. Springer, New York (2003) 5. Huzurbazar, A., Williams, B.: Incorporating Covariates in Flowgraph Models: Applications to Recurrent Event Data. Technometrics. 52, 198-208 (2010) 6. Collins, D.H., Huzurbazar, A.V.: System reliabyility and safety assessment using non-parametric flowgraph models. Proc. IMechE Part O: J. Risk and Reliability. 222, 667 674 (2008) 7. Huzurbazar, A.: Flowgraph Models for Multistate -To-Event Data. Wiley, New York (2005) 8. Collins, D.H., Huzurbazar, A.V.: Prognostic models based on statistical flowgraphs. Appl. Stochastic Models Bus. Ind. 28, 141 151 (2012) 9. Pérez-Ocón, R.; Segovia. M.C.: Modeling lifetimes using phase-type distributions. In: Aven, T., Vinnem, J.E. (eds.) Risk, Reliability and Societal Safety, Proceedings of the European Safety and Reliability Conference 2007 (ESREL 2007), Taylor & Francis,3rd edition (2007) 10. Mullen, K.M.; van Stokkum, I.H.: nnls: the Lawson-Hanson algorithm for nonnegative least squares (NNLS) http://www.r-project.org IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 553